Home
About Us
Our Company
Our Leadership Team
Board of Directors
Technology
Our Tobacco Technology
Our Cannabis/Hemp Technology
VLN Clinical Studies
Published Clinical Studies
On-Going Clinical Studies
Commentaries & Opinion
Products
SPECTRUM® Variable Nicotine Research Cigarettes
Moonlight®
VLN®
Investors
Overview
New Investor / Latest Resources
Events
News
Stock Data
SEC Filings
Analyst Coverage
Corporate Governance
Annual Reports
FAQs
News
Contact Us
New Investor / Latest Resources
Investors
Investors
Overview
New Investor / Latest Resources
Events
News
Press Releases
Stock Data
Quote
Charts
Historical Data
Trades
SEC Filings
Analyst Coverage
Corporate Governance
Annual Reports
FAQs
Below are a few links to help you quickly become familiar with 22nd Century Group.
View Investor Presentation
2021 Priorities & Areas of Focus (Slide 5)
2021 Developments: Tobacco and Hemp/Cannabis (Slides 12 and 18)
22nd Century Investment Highlights (Slide 22)
CEO Letter
Factsheet
Q1 2021 Earnings Results Webcast
Earnings Presentation
Earnings Transcript
Earnings Release
Webcast
Form 10-Q
Press Releases
22nd Century Fully Prepared to Deliver the Solution as Biden Administration Considers Requirement to Lower Nicotine Level for All Cigarettes Sold in U.S.
Multiple former FDA Commissioners Voice Support For Reduced Nicotine Mandate; Proposed Legislation Would be Game-Changing for 22nd Century
22nd Century Group Issues Annual Letter to Shareholders
22nd Century Group and KeyGene Extend and Expand Plant Research Partnership
Email Alerts
Contact
RSS News Feed